REFERENCIAS BIBLIOGRÁFICAS

1. Choi C. Manegement of tuberculosis: special considerations. Dis Manage Health Outcomes 1998; 4 (4):205-16.

2. Tuberculosis in latin America and Caribbean. Boletín de la Organización Panamericana de Salud. 1997.16-44.

3. Dolin PJ, Raviglione MC. Glohal Tuberculosis incidence and mortality during 1990-2000. Hull World Heath Organ 1994; 72: 213-20.

4. Ministerio de Salud. Tuberculosis en el Perú. Evaluación del Programa Nacional del Control de la Tuberculosis en el Perú. Informe 2000. Pag. 42-43.

5. American Thoracic Society guidelines: Control of Tuberculosis in the US; Pre­vention; compliance data colletion and analysis; and summary. Am Rev Respir Dis 1992; 46: 1623.

6. Pilheu J. A. Tuberculosis 2OOO: problems and solutions. Int J Tuberc Lung Dis 1998; 2 (9): 696-703.

7. Unión Internacional de contra la Tuberculosis. Commitee on Profilaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982; 0: 555.

8. Weiss SE, Slocum PC, et a. The effect of directly observed on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330 (7):1179-84.

9. Chaulk Cp Moore-Rice K, et al. Eleven years of community-based observed therapy for tuberculosis. JAMA 1995; 274 (12): 945-51.

10. Burman WJ, Cohn DL, Rietnicijer CA, et al Noncompliance with directly ob­served therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997; 111 (5): 1168-73.

11. Camere-Torrealva MA. Seguimiento y Morbimortalidad de los pacientes del Programa de Control de Tuberculosis del Hospital General Base Cayetano Heredia de 1972 a 1979. Tesis de Bachiller, 1982.

12. Iseman M, Huitt G.Tuberculosis. Clinics in Chest Medicina 1997, 18 (1): 1- 155.

13. Carcelén A. Accinelli R, Camacho J, Pineiro Villarán. Evaluación del Programa de Control de Tuberculosis del Hospital Cayetano Heredia. XI Congreso de Tisioneumología. Lima, Perú. 1980

14. Accinelli R, Espinoza Y, Reyes M,Silva V, Javo O. Results of the Directly observed Theraphy with 2RIPE 4R212 in 15 250 smear positive pulmonary tuberculosis patients in Lima, Perú. Am J Respir Crit Care Med 1998; Abstract: A488.

15. Hopewell P. Global tuberculosis control: an optimist's perpective. Int J Tuberc Lung Dis 1999; 3 (4): 270-2.

16. Farmer P. Editorial. Managerial successes, clinical failures. Int J Tuberc Lung Dis 1999; 3 (5):365-7.

17. Farmer P, Yong K. Community hased approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-Plus". BMJ 1998; 317.671-4-

18. Farmer P, Hayonaj, Hecerra M, et al. The dilemrna of MDR -TH in the global era. Int J Tuberc Lung Dis 1998; 2: 869-76.

19. Farmer PE, Bayona J, Becerra M, ShinS, NuñezC, Nardell E. International Working Group on Multidrug Resistant Tuberculosis. The emergence of MDRTH in urhan Peru: apopulation-based study using conventional, molecular and ethno-graphic methods. Conference on Global Lung Disease, Paris, October 1-4,1997.

20. Turett G, Telzak E, Torian L, Blum S, et al. Improved Outcomes for Patients with Multidrug- Resistant Tuberculosis. Clin Infect Dis 1995; 21: 1238-44.

21. Kritsky AL, Rodríguez de Jesús LS, et al. Retratment Tuberculosis cases. Factors associatedwith drug resistance and adverse outcome. Chest 1997,111: 1162-7.

22. Dawson Saunders H. Bioestadística Médica. Ed Manual Moderna 2da edición. Méjico DE 1997.

23. Mlika-Cabanne N, Brauner M, Mugusi P et al. Radiographic Ahnormalities in Tuberculosis and Risk fo Coexisting Human Inimunodeficiency Virus Infection. Am J Respir Crit Care Med 1995; 152: 786-92.

24. León-Barúa R. Estrés, desórdenes emocionales y enfermedad. El papel de lo psicológico en la medicina. Diagnóstico 1999; 38 (1): 22-8.

25. Beck, et al. An Inventary for measuring depression. Arch Scand Psychiatry 1961; 4: 561-71.

26. Novara J, Sotillo C, Warthon D. Estandarización y correlación de las escalas de Beck, Hamilton y Zung para depresión en la población de Lima Metropolitana. Primer Informe Técnico 1983, INSM HD-HN.

27. Ministerio de Salud. Tuberculosis en el Perú. Evaluación del Program­ del Control de la Tuberculosis en el Perú. Informe 1997,

28. WHO. Antituberculosis drug resistance in the world. The WHO/IUATLD glo­bal project on antituberculosis drug resistance surveillanca 1994-1997. Ge­neva. WHO 1997.

29. Valenzuela P. Utilidad de los estudios a medicamentos antituberculosos. Rev Panam Salud Pública/Pan Am J Public Health 1997,1: 62-7.

30. Espinal MA, Kiim SJ, Hong YP, et al. Treatment outcome of multidrugresistant tuberculosis cases under programme conditions. Int J Tuberc Lung Dis 1998; 2: S371.

31. Salomon N, Perlman P Predictors and outcomes of multidrug-resistant tuberculosis. Clinical Infectious Diseases. 1995; 21: 1245-52.

32. Fujiwara PI, Cook SV, Rutherford CM, Crawford JT, Glicknian SE, Kreiswirth HN. A continuing survey of drug resistant tuberculosis, New York City April 1994. Arch Intern Med 1997; 10; 157 (5): 531-6.

33. Frieden T, SterlingT, Pahtos Mendez A. The Emergence of Drug-Resistant Tuberculosis in New York City. N Enl J Med 1993; 328: 521-6.

34. Githui W, Juma ES, Gorkom J, Kihuga D, Odhiamho J, Drobniewski F. Antituberculosis drug resistance surveillance in Kenya, 1995. Int J Tuberc Lung Dis 1998; 2 (6): 499-505.

35. Saya N, Satnca-Circioiu, et al. Failums of standardized treatments in TBC pul­monary tuberculosis. Posibilites of prevention and therautic. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumaftiziol 1981; 30 (3): 165-72.

36. CDC Prevention Guidelines. Screening for Tuberculosis and Infection in High ­Risk Populations Recommendations of the Advisory Council for the Elimina­tion of Tuberculosis. MMWR. 1995;44 (RR- II); 18-34.

37. Kritski AL, Marques MJ, Rabani MF. Transmission of tuberculosis to close con­tacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153 (1): 331-5.

38. Lineamientos para manejo del paciente con Tuberculosis multirresitente. Sociedad Peruana de Neumología. Diciembre 1997. Lima, Perú.

39. Dyspnea. Mechanicsnis, assesment and manegement: A consensus statement Am J Respir Crit Care Med 1998; 159: 246-251.

40. Pamo 0, Ojeda F. Tuberculosis y estado nutricional. Diagnóstico 1988; 21 (3): 77-85.

41. Vidal R, Casabona M, et al. Incidence and significance of acid-fast bacilli in sputum smears at the end of antituberculosis treatment Chest 1996; 109:1562-65.

42. Mohamed S, AI-Moamary, BlackW, et al. The significance of the persistent presence of acid-fast bacilli in sputum smear in Pulmonary tuberculosis. Chest 1999; 116: 725-31.

43. Organización Panamericana de la Salud, Oficina Sankaria Panamericana, Oficina Regional de la Organización Mundial de la Salud. Programa de enfermedades transmisible. División de Prevención y Control de Enfermedades Transmisibles. El Conocimiento actual en Tuberculosis. Washington, D.C. Julio 1993.

44. Bastian I, Colebunders R-Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999; 58 (4):633-66 1.

45. Schluger N, William R. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-91.

Regresar